Market closed
Apellis Pharmaceuticals/$APLS
13:30
09:10
04:45
00:25
20:00
1D1W1MYTD1Y5YMAX
About Apellis Pharmaceuticals
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
Ticker
$APLS
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
708
Website
APLS Metrics
BasicAdvanced
$2.9B
-
-$1.60
0.92
-
Price and volume
Market cap
$2.9B
Beta
0.92
52-week high
$58.12
52-week low
$21.70
Average daily volume
2M
Financial strength
Current ratio
4.253
Quick ratio
3.708
Long term debt to equity
202.605
Total debt to equity
205.56
Interest coverage (TTM)
-4.08%
Management effectiveness
Return on assets (TTM)
-12.32%
Return on equity (TTM)
-93.55%
Valuation
Price to revenue (TTM)
3.647
Price to book
12.53
Price to tangible book (TTM)
12.53
Price to free cash flow (TTM)
-32.286
Growth
Revenue change (TTM)
97.02%
Earnings per share change (TTM)
-64.15%
3-year revenue growth (CAGR)
127.27%
3-year earnings per share growth (CAGR)
-43.47%
What the Analysts think about APLS
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Apellis Pharmaceuticals stock.
APLS Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
APLS Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
APLS News
AllArticlesVideos
FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals
Benzinga·2 days ago
Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN
GlobeNewsWire·2 days ago
Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan Analyst
Benzinga·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Apellis Pharmaceuticals stock?
Apellis Pharmaceuticals (APLS) has a market cap of $2.9B as of April 03, 2025.
What is the P/E ratio for Apellis Pharmaceuticals stock?
The price to earnings (P/E) ratio for Apellis Pharmaceuticals (APLS) stock is 0 as of April 03, 2025.
Does Apellis Pharmaceuticals stock pay dividends?
No, Apellis Pharmaceuticals (APLS) stock does not pay dividends to its shareholders as of April 03, 2025.
When is the next Apellis Pharmaceuticals dividend payment date?
Apellis Pharmaceuticals (APLS) stock does not pay dividends to its shareholders.
What is the beta indicator for Apellis Pharmaceuticals?
Apellis Pharmaceuticals (APLS) has a beta rating of 0.92. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.